We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+1.21%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
AUM
$1.9B
AUM Growth
-$88M
Cap. Flow
-$194M
Cap. Flow %
-10.24%
Top 10 Hldgs %
47.92%
Holding
151
New
44
Increased
37
Reduced
36
Closed
31

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$48.5M
2
DHR icon
Danaher
DHR
+$42.6M
3
VERA icon
Vera Therapeutics
VERA
+$38.7M
4
VRDN icon
Viridian Therapeutics
VRDN
+$31.7M
5
BRKR icon
Bruker
BRKR
+$27.9M

Sector Composition

Rank Sector Weight
1 Healthcare 74.35%
2 Miscellaneous 20.04%
3 Real Estate 5.59%
4 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
XENE icon
51
Xenon Pharmaceuticals
XENE
$5.81B
$7.53M 0.4%
129,574
-101,806
-44% -$4.69M
RVTY icon
52
Revvity
RVTY
$14.4B
$7.43M 0.39%
84,854
-77,923
-48% -$7.72M
AGIO icon
53
Agios Pharmaceuticals
AGIO
$1.99B
$6.77M 0.36%
+200,000
New +$5.67M
GPCR icon
54
Structure Therapeutics
GPCR
$3.38B
$6.65M 0.35%
138,036
+10,475
+8% +$717K
TECH icon
55
Bio-Techne
TECH
$11.3B
$6.58M 0.35%
125,896
-251,509
-67% -$15.1M
GKOS icon
56
Glaukos
GKOS
$10.6B
$6.48M 0.34%
60,214
-87,257
-59% -$9.82M
THC icon
57
Tenet Healthcare
THC
$21.5B
$5.57M 0.29%
+29,512
New +$6.22M
MDGL icon
58
Madrigal Pharmaceuticals
MDGL
$12.3B
$5.23M 0.28%
+10,000
New +$4.78M
ISRG icon
59
Intuitive Surgical
ISRG
$132B
$5.13M 0.27%
11,119
-6,943
-38% -$3.51M
PRAX icon
60
PUT
Praxis Precision Medicines
PRAX
$9.63B
$4.77M 0.25%
+14,800
New +$4.58M
ESPR
61
DELISTED
Esperion Therapeutics
ESPR
$4.76M 0.25%
1,735,963
-2,115,170
-55% -$6.7M
MOH icon
62
Molina Healthcare
MOH
$10.4B
$4.37M 0.23%
32,811
-12,659
-28% -$2.01M
HQY icon
63
HealthEquity
HQY
$7.97B
$4.31M 0.23%
51,614
-134,125
-72% -$11M
BRKR icon
64
Bruker
BRKR
$8.7B
$4.23M 0.22%
117,013
-666,776
-85% -$27.9M
DAWN
65
DELISTED
Day One Biopharmaceuticals
DAWN
$3.94M 0.21%
+183,902
New +$2.59M
XBI icon
66
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$3.83M 0.2%
30,000
-69,400
-70% -$8.66M
CMPS
67
Compass Pathways
CMPS
$1.9B
$3.75M 0.2%
+677,924
New +$4.56M
CNC icon
68
Centene
CNC
$32B
$3.66M 0.19%
111,652
-212,440
-66% -$8.71M
GRCE
69
Grace Therapeutics
GRCE
$44.6M
$3.5M 0.18%
+756,600
New +$2.97M
ENGN icon
70
enGene Therapeutics
ENGN
$122M
$3.48M 0.18%
510,543
+54,708
+12% +$487K
UHS icon
71
PUT
Universal Health Services
UHS
$10.1B
$3.26M 0.17%
+18,200
New +$3.74M
EHAB
72
DELISTED
Enhabit
EHAB
$3.2M 0.17%
227,451
+8,941
+4% +$107K
XLE icon
73
CALL
State Street Energy Select Sector SPDR ETF
XLE
$41.2B
$3.06M 0.16%
+50,000
New +$2.68M
DFTX
74
Definium Therapeutics
DFTX
$5.51B
$3.04M 0.16%
+160,723
New +$2.73M
EQ icon
75
Equillium
EQ
$152M
$3M 0.16%
+1,498,993
New +$2.47M

Similar funds

Eversept Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Eversept Partners held 151 positions worth $1.9B, down 4.4% from $1.98B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Eversept Partners withdrew a net $194M in Q1 2026, closing 31 positions and reducing 36 holdings. Its most notable exit was Danaher, an estimated $42.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 90% a quarter earlier, followed by Miscellaneous and Real Estate.

Against the trend, Eversept Partners opened a new position in Welltower worth $35.8M.

  • Eversept Partners's largest Q1 2026 buy was Welltower: 180,953 shares worth $35.8M.
  • Eversept Partners added most to Brookdale Senior Living in Q1 2026, an estimated $44.7M increase.
  • Eversept Partners's biggest Q1 2026 reduction was GSK, cutting an estimated $48.5M.
  • Eversept Partners fully exited Danaher in Q1 2026, selling an estimated $42.6M.
  • Eversept Partners's ten largest holdings make up 48% of its $1.9B portfolio in Q1 2026.
  • Eversept Partners opened 44 new positions and closed 31 in Q1 2026.
  • Eversept Partners's portfolio value fell 4.4% quarter-over-quarter to $1.9B.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.